Impact of EGFR tyrosine kinase inhibitors in the management of brain metastases from EGFR-mutated and wild-type (WT) non-small cell lung cancer (NSCLC): A survival analysis. This is an ASCO Meeting ...
Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...
Please provide your email address to receive an email when new articles are posted on . First-line treatment with afatinib significantly prolonged time-to-treatment failure compared with gefitinib for ...
Get detailed information on Afatinib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...
The author(s) indicated no potential conflicts of interest. Corresponding author: Antonio Passaro, MD, Division of Thoracic Oncology, European Institute of Oncology, Via G. Ripamonti, 435 –20141, ...
Patients with advanced non–small cell lung cancer who harbored EGFR exon 19 deletions and who received first-line treatment with afatinib achieved significantly prolonged OS compared with patients who ...
The study offers guidance to clinicians treating the roughly 10% of patients with rare EGFR mutations. Patients with non–small cell lung cancer (NSCLC) who have uncommon EGFR mutations appear to have ...
LUX-Lung 3 results highlighted at the official ASCO Press Conference: Afatinib* delays cancer progression significantly more than the best standard chemotherapy Ingelheim, Germany, 4 June 2012 –The ...
• Afatinib comes as a tablet which should be taken by mouth on an empty stomach preferably either two hours after a meal or one hour before a meal. • Never take afatinib tablets in smaller or larger ...
Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have ...
Afatinib significantly improves progression-free survival among patients with advanced lung cancer that harbors certain genetic mutations compared with standard chemotherapy. Results from a phase 3 ...
Afatinib improves progression-free survival compared with cisplatin and pemetrexed as first- line treatment for patients with EGFR mutant lung cancers Afatinib monotherapy has limited efficacy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results